Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology
LIXTE Biotechnology Holdings, a biotech company focused on advancing cancer treatments, announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers.
Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora’s proprietary flagship technology LiGHT System (Linac for Image Guided Hadron Therapy), which provides significant advantages over currently available technologies for treating tumors with proton therapy.
Liora’s LiGHT system is installed at STFC’s Daresbury Laboratory, which will be providing resources to develop a center of excellence for proton therapy treatment using the LiGHT system.
“The acquisition of Liora represents our entry in the radiotherapy segment of cancer care and marks a significant step in LIXTE’s corporate growth and development as we aim to fulfill our mission of treating cancer with cutting-edge technologies,” said Geordan Pursglove, CEO of LIXTE. “We believe that Liora’s flagship technology LiGHT System has significant global potential and could well set a new gold standard in cancer care, delivering high-precision proton therapy that is scalable and clinically versatile.”
Read More: SalesTechStar Interview with Sahil Rekhi, Chief Revenue Officer at Graia
Professor Steve Myers, former Director of Accelerators and Technology at CERN, the European Organization for Nuclear Research, said, “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors. In addition to the unique biological effects, it will also greatly reduce the installation cost and the number of treatment sessions needed, compared to current technologies, and is expected to significantly increase the number of patients that a treatment center can serve. With LIXTE’s acquisition of Liora’s assets, I am excited to see how the Company advances and scales this technology. I believe there is tremendous potential to turn this into a transformative new standard in cancer treatment.”
“Our plan is to bring the LiGHT system to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model through jointly operated treatment centers. The addition of Liora also represents an excellent complement to the pharmaceutical side of our business and our ongoing clinical trials with LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer,” Pursglove added.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
Read More: Beyond CRM: How SalesTech is Shaping the Future of Deal Management?